8-K: Elevance Health Reports 2025 Results, Sets Cautious 2026 Outlook

Elevance Health announced its fourth quarter and full year 2025 results, reporting robust revenue growth and shareholder returns while setting a cautious outlook for 2026.

Summary

• Operating revenue reached $49.3 billion in Q4 2025, a 10% increase year-over-year, and $197.6 billion for the full year 2025, up 13%.
• Diluted EPS for Q4 2025 was $2.47, with adjusted diluted EPS at $3.33.
• Full year 2025 diluted EPS was $25.21, and adjusted diluted EPS was $30.29.
• The company projects FY 2026 GAAP diluted EPS to be at least $22.30 and adjusted diluted EPS to be at least $25.50.
• Elevance Health returned $4.1 billion of capital to shareholders in 2025.
• The benefit expense ratio increased to 93.5% in Q4 and 90.0% for the full year, driven by higher medical cost trends, particularly in Affordable Care Act health plans and Medicare Part D seasonality.
• Medical membership decreased by 0.5 million, or 1%, year-over-year to approximately 45.2 million as of December 31, 2025, primarily due to attrition in the Medicaid business.
• Operating cash flow for 2025 was $4.3 billion.

Sentiment

Score: 4

Explanation: While the company achieved strong revenue growth and returned significant capital to shareholders in 2025, profitability metrics (EPS, operating gain) declined year-over-year. The 2026 outlook projects further declines in EPS and total operating revenue, along with membership attrition, indicating challenges ahead despite management's confidence in a 2027 rebound. This mixed performance and cautious near-term outlook result in a moderately negative sentiment.

Positives

• Strong operating revenue growth of 10% in Q4 2025 ($49.3 billion) and 13% for FY 2025 ($197.6 billion), driven by higher premium yields, acquisitions, and Medicare Advantage membership growth.
• Significant capital returned to shareholders, totaling $4.1 billion in 2025, including $471 million in share repurchases during Q4 2025.
• Increased quarterly dividend declared for Q1 2026 to $1.72 per share, up from $1.71 per share.
• Carelon segment demonstrated robust revenue growth of 27% in Q4 ($18.7 billion) and 33% for FY 2025 ($71.7 billion), attributed to CarelonRx product revenue, expansion of Carelon Services risk-based solutions, and the acquisition of CareBridge.
• Carelon's full-year adjusted operating gain increased by 10% to $3.4 billion.
• Maintained expense discipline while investing in workforce, Carelon capabilities, and technology adoption across the enterprise.

Negatives

• Full year 2025 GAAP diluted EPS ($25.21) and adjusted diluted EPS ($30.29) declined compared to FY 2024 ($25.68 and $33.04, respectively).
• Operating gain and adjusted operating gain for Q4 2025 significantly decreased compared to Q4 2024, with operating gain falling from $0.7 billion to $0.3 billion and adjusted operating gain from $0.8 billion to $0.4 billion.
• Full year 2025 operating gain decreased to $7.2 billion from $7.9 billion in 2024.
• Benefit expense ratio increased by 110 basis points in Q4 and 150 basis points for the full year, reflecting higher medical cost trends.
• Medical membership decreased by 1% year-over-year, primarily due to attrition in the Medicaid business.
• The Health Benefits segment reported an adjusted operating loss of $0.2 billion in Q4 2025.
• Projected FY 2026 GAAP diluted EPS (at least $22.30) and adjusted diluted EPS (at least $25.50) are lower than FY 2025 actuals.
• Projected low single-digit decline in total operating revenue for FY 2026.
• Projected decline in medical enrollment for FY 2026 across Commercial Risk-Based, Medicaid, Medicare Advantage, Medicare Supplement, and Federal Employee Program segments.

Risks

• Trends in healthcare costs and utilization rates.
• Reduced enrollment across various health plans.
• Ability to secure and implement sufficient premium rates.
• Impact of large-scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes.
• Impact of new or changes in existing federal, state, and international laws or regulations, including those impacting healthcare, insurance, pharmacy services, and other diversified products and services, or their enforcement or application.
• Impact of cyber-attacks or other privacy or data security incidents or failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto.
• Failure to effectively maintain and modernize information systems, or failure of information systems or technology, including artificial intelligence, to operate as intended.
• Failure to effectively maintain the availability and integrity of data.
• Changes in economic and market conditions, as well as regulations that may negatively affect liquidity and investment portfolios.
• Competitive pressures and ability to adapt to changes in the industry and develop and implement strategic growth opportunities.
• Risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with complex regulations.
• Ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks.
• A negative change in healthcare product mix.
• Costs and other liabilities associated with litigation, government investigations, audits or reviews.
• Ability to contract with providers on cost-effective and competitive terms.
• Risks associated with providing healthcare, pharmacy, and other diversified products and services, including medical malpractice or professional liability claims and non-compliance with pharmacy services agreements.
• Effects of any negative publicity or sentiment related to the health benefits industry in general or the company in particular.
• Risks associated with mergers, acquisitions, joint ventures, and strategic alliances.
• Possible impairment of the value of intangible assets if future results do not adequately support goodwill and other intangible assets.
• Possible restrictions in the payment of dividends from subsidiaries and increases in required minimum levels of capital.
• Ability to repurchase shares of common stock and pay dividends due to the adequacy of cash flow and earnings and other considerations.
• Potential negative effect from substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact access to or further increase the cost of financing.
• A downgrade in financial strength ratings.
• Events that may negatively affect licenses with the Blue Cross and Blue Shield Association.
• Intense competition to attract and retain employees.
• Risks associated with international operations.
• Various laws and provisions in governing documents that may prevent or discourage takeovers and business combinations.

Future Outlook

Elevance Health projects FY 2026 GAAP diluted EPS to be at least $22.30 and adjusted diluted EPS to be at least $25.50. The company anticipates a low single-digit decline in total operating revenue for FY 2026, with a benefit expense ratio of 90.2% +/50 bps and an adjusted operating expense ratio of 10.6% +/50 bps. Operating cash flow is expected to be at least $5.5 billion. The company is recalibrating segment margin targets and reaffirms its long-term earnings algorithm, expressing confidence in returning to at least 12% adjusted EPS growth in 2027.

Management Comments

• "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment."
• "As we enter 2026, our focus is on advancing affordability and making healthcare easier to access and navigate for the members we serve."
• "Through pricing discipline and targeted investments, we are strengthening the earnings power of our diversified platform and remain confident in our ability to return to at least 12% adjusted EPS growth in 2027."

Industry Context

The filing indicates a dynamic healthcare environment characterized by higher medical cost trends, particularly impacting Affordable Care Act health plans and Medicare Part D due to Inflation Reduction Act changes. Membership attrition in the Medicaid business suggests potential impacts from state redetermination processes or competitive shifts. The strong growth in the Carelon segment (CarelonRx and Carelon Services) highlights a strategic pivot towards diversified health services and integrated care solutions, aligning with broader industry trends to expand beyond traditional insurance offerings and address the full spectrum of healthcare needs.

Legal Proceedings

• Litigation and settlement expenses were $5 million in Q4 2025 and $24 million for FY 2025, down from $12 million and $692 million in the respective 2024 periods, indicating ongoing financial impacts from such matters.
• The company faces risks related to costs and other liabilities associated with litigation, government investigations, audits, or reviews.

Stakeholder Impact

• Shareholders: Positive impact from $4.1 billion in capital returns in 2025 and an increased Q1 2026 dividend of $1.72 per share. Potential negative impact from declining EPS and revenue outlook for 2026.
• Members: The company's focus for 2026 is on advancing affordability and making healthcare easier to access and navigate. Membership attrition in Medicaid could affect some member populations.
• Employees: The company is investing to support and strengthen its workforce.
• Providers: Risks are noted regarding the company's ability to contract with providers on cost-effective and competitive terms.

Next Steps

• Focus on advancing affordability and making healthcare easier to access and navigate for members in 2026.
• Strengthening the earnings power of the diversified platform through pricing discipline and targeted investments.
• Aims to return to at least 12% adjusted EPS growth in 2027.
• Management will host a conference call and webcast on January 28, 2026, at 8:30 a.m. EST to discuss the results and 2026 outlook.
• Payment of the first quarter 2026 dividend on March 25, 2026.

Key Dates

Recommendation

Elevance Health demonstrates strong revenue growth and a commitment to shareholder returns through dividends and buybacks. However, the decline in full-year EPS for 2025 and the projected further decline in 2026, coupled with membership attrition in key segments like Medicaid, signal headwinds. While management expresses confidence in a 2027 rebound, the immediate outlook suggests a period of recalibration and investment. A 'Hold' recommendation is appropriate for investors to monitor the execution of strategic initiatives, particularly the efforts to manage medical cost trends and stabilize membership, before considering further investment or divestment. The diversified Carelon segment shows promise, but its growth needs to offset challenges in the Health Benefits segment.

Keywords

Healthcare, Health Insurance, Managed Care, Elevance Health, ELV, Earnings Report, Financial Results, Q4 2025, Full Year 2025, 2026 Outlook, Medicare Advantage, Medicaid, Carelon, CarelonRx, EPS, Revenue, Medical Costs, Share Repurchase, Dividend